|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM247509191 |
| 003 |
DE-627 |
| 005 |
20231224145359.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2015 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2015.03.016
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0825.xml
|
| 035 |
|
|
|a (DE-627)NLM247509191
|
| 035 |
|
|
|a (NLM)25817545
|
| 035 |
|
|
|a (PII)S1521-6616(15)00116-3
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Garciafigueroa, Yesica
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A brief glimpse over the horizon for type 1 diabetes nanotherapeutics
|
| 264 |
|
1 |
|c 2015
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 22.12.2015
|
| 500 |
|
|
|a Date Revised 31.08.2015
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2015 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a The pace at which nanotherapeutic technology for human disease is evolving has accelerated exponentially over the past five years. Most of the technology is centered on drug delivery which, in some instances, offers tunable control of drug release. Emerging technologies have resulted in improvements in tissue and cell targeting while others are at the initial stages of pairing drug release and drug release kinetics with microenvironmental stimuli or changes in homeostasis. Nanotherapeutics has only recently been adopted for consideration as a prophylaxis/treatment approach in autoimmunity. Herein, we summarize the current state-of-the art of nanotherapeutics specifically for type 1 diabetes mellitus and offer our view over the horizon of where we envisage this modality evolving towards
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Autoimmunity
|
| 650 |
|
4 |
|a Diabetes
|
| 650 |
|
4 |
|a Immunotherapy
|
| 650 |
|
4 |
|a Nanoparticles
|
| 650 |
|
4 |
|a Nanotherapeutics
|
| 650 |
|
4 |
|a Tolerance
|
| 700 |
1 |
|
|a Trucco, Massimo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Giannoukakis, Nick
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 160(2015), 1 vom: 15. Sept., Seite 36-45
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:160
|g year:2015
|g number:1
|g day:15
|g month:09
|g pages:36-45
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2015.03.016
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 160
|j 2015
|e 1
|b 15
|c 09
|h 36-45
|